Abstract-We present a 6.Smm 3 , lOmg, wireless peripheral nerve stimulator. The stimulator is powered and controlled through ultrasound from an external transducer and utilizes a single 7S0x7S0x7S0pm 3 piezocrystal for downlink communication, powering, and readout, reducing implant volume and mass. An IC with O.06mm 2 active circuit area, designed in TSMC 6Snm LPCMOS process, converts harvested ultrasound to stimulation charge with a peak efficiency of 82%. A custom wireless protocol that does not require a clock or memory circuits reduces on-chip power to 4pW when not stimulating. The encapsulated stimulator was cuffed to the sciatic nerve of an anesthetized rodent and demonstrated full-scale nerve activation in vivo. We achieve a highly efficient and temporally precise wireless peripheral nerve stimulator that is the smallest and lightest to our knowledge.
I. INTRODUCTION
Peripheral nerve stimulators (PNSs) have shown promise in the symptomatic treatment a variety of disorders such as chronic pain , sleep apnea, incontinence, and arthritis [I] , [2] . A primary technological barrier to widespread adoption of peripheral nerve stimulators is the need for a wireless, mmscale system that can be implanted through minimally invasive procedures. Recent PNS research has focused on the development of small volume, battery-less systems that are capable of safe and efficient power transfer centimeters into tissue [2] - [4] . Typically, PNSs only require a single electrode pair to stimulate the nerve. Recently, ultrasound has been proposed as an efficient way to power and communicate with mmscale implants in deep tissue, resulting in significant volume reduction [2] , [3] . Compared to RF at 2GHz, ultrasound energy at 2MHz has less attenuation through tissue (I dB/cm vs. 3dB/cm), a higher FDA limit (7.2mW/mm 2 vs. 0.lmW/mm
2 ) , and smaller wavelength (0.75mm vs. 25mm) [I] . We present a 10mg, 6.5mm 3 peripheral nerve stimulator that uses a single piezocrystal for power and bidirectional communication with ultrasound, and efficiently converts received power to provide well-controlled stimulation to the nerve. The smallest volume stimulators [3] , [4] have been implemented with passive components, providing inefficient voltage-mode stimulation that is sensitive to received power and electrode impedance. Active, multi-channel neurostimulators utilizing inductive coupling have achieved high efficiencies [5] , [6] , but require em-scale coils and occupy 978-1-5386-2483-8/18/$31.00 ©2018 IEEE Fig. 1 . System illustration of the implantable device. The implant is wirelessly powered via harvested ultrasound from a piezo crystal. By detectin g the envelope of incomin g ultrasound , the stimulation IC dynamically reconfigures stimulation pulse width, pulse interval , interphase gap , and amplitude. larger volumes. This work scales down the volume of the implant by using a single piezocrystal coupled to an IC and wireless protocol that achieves high efficiency and precision. High efficiency is achieved through a combination of protocol design, duty cycling, active rectification, and reducing the need for high voltage compliance stimulation. For precision, the stimulation IC utilizes a current-mode stimulator to deliver a well-controlled charge independent of electrode size and impedance, which can be highly variable at small scales. The stimulation waveform is dynamically reconfigurable via the structure of the input ultrasound, rather than bit packets. The protocol enables sub-us temporal precision of the stimulation waveform without the need for a clock, and an inherently high dynamic range of pulse widths and frequencies (e.g. f st im = 0-2kHz), while minimizing complexity and therefore power.
II . SYSTEM ARCHITECTURE Fig. I depicts the system concept. The implanted stimulation mote is cuffed to a peripheral (e.g. sciatic) nerve while an external transducer powers and controls the mote with ultrasound. The external transducer is driven by a custom ASIC that level-shifts the microcontroller-generated ultrasound transmit signal [7] . The maximum drive voltage of the ex- 
III . SYSTEM CHARACTERIZATION
The IC is fabricated in TSMC 65nm LP-CMOS proce ss and occupies an area of Imm' (Fig. 3) . The active area is 150x400p,m 2 . Fig. 3 also shows the mote assembly, which measures 2x3.25x Imrn:' and 10mg. The height is dominated by the 750p,m tall piezo and wire bond on a 100p,m-thick polyimide PCB . A 4p,F 0201 surface mount capacitor is used to store energy for high -capacity stimulation. A IOrzmthick conformal layer of parylene is used to encapsulate the entire mote. A thin encapsulation layer ensures good acoustical transmission between the surrounding tissue and the piezo. The back of the mote features two 550x550p,m 2 Au electrodes (stirn and return) electroplated with PEDOT:PSS. The PEDOT:PSS coating reduces the electrode imped ance several orders of magnitude at low frequency, reducing the ternal transducer in this implementation is 32V, resulting in the piezo terminals for backscatter. The impedance change is rv350p,W maximum received power in the implant. Depending sufficient to serve as a I-bit indicator flag (measurement shown on protocol, stimulation powers can match or even exceed in Fig. 6 ), while allowing all circuits on the IC to function this value, making conversion efficiency from received power normally under reduced voltage conditions. For efficiency, an to stimulation power essential. The implanted mote consists active full-wave rectifier converts the piezo voltage (3V-5V) of the stimulation IC, a piezocrystal, and a charge storage to a nominal 2.5V supply. An LDO regulates a IV supp ly for capacitor mounted on a flexible PCB with two electrodes on the digital control circuitry. The rectifier comparator outputs the bottom side. The incident ultrasound wave is reflected are also used to drive the watchdog switches. The sensitivity back to the external transducer with a magnitude related to of the watchdog is increased during stimulation using lowthe electrical load impedance seen by the piezo. This load voltage devices to account for the reduced voltage at the impedance is modulated by the stimulation IC to provide a piezo terminals. The TDC consists of 8 current-starved inverter single bit that indicates chip state (stimulation on or off), for delay stages to generate a 3-bit amplitude code. The unit safety.
delay is designed to be greater than twice the watchdog time The protocol utilizes edge -detection to encode for timing , constant to be insensitive to piezo ring-down as well as process rather than clocks, which reduces power consumption while variations controlling the watchdog time constant, which is set simultaneously provides a high degree of timing control and by an Re. To further conserve power, most subcircuits are precision. As shown in the timing diagram of Fig. 2 , an initial heavily duty-cycled, where corresponding numbers in Fig. 2 power-up sequence charges the implants storage capacitor and indicate the phase when a particular subcircuit is active. For a POR signal initializes the system. A watchdog timer is example, the clock extractor is only active to generate the 16-used to detect ultrasound-free intervals (UFIs) in the incoming cycle header, which ensures proper settling of the constant-gm ultrasound. For every UFI , the stimulation state is toggled . current reference. The first UFI length encodes the stimulation amplitude, which is decoded with a 3-bit TDe. The next burst of ultrasound generates the stimulation command; a 16-clock cycle header generates a delay to allow bias circuitry to settle prior to stimulation. After the header, the stimulation current source and the modulation switch (for backscattering) are enabled. A single bit is back scattered in this phase to indicate whether or not the mote is stimulating as a safety indication. A second UFI encodes the interphase gap , a feature shown to have an impact on stimulation thresholds. The next ultrasound burst enables a shorting phase that clears accumulated charge from the stimulation electrode. Since high capacity stimulation discharges the storage capacitor, this phase is also used for recharging the capacitor. ~~--.--,-~,.......,~--.--,--.--,.......,~---.--,--.--.,. ....., required stimulation headroom and eliminating the need for high voltage circuits, improving chip efficiency (Fig . 4) . Furthermore, a lower supply voltage enables the use of higher density capacitors with lower voltage ratings. Fig. 5 shows the measured output current versus UFIlength and the chip efficiency. While the relative error between current levels of the DAC or TDC steps is small, the absolute error will be sensitive to process variation. However, this is easily calibrated by adjusting the protocol with the external system. The overall chip efficiency When not stimulating, the DC power is measured to be 4{LW. When stimulating, the total power dissipation is roughly PTO T =2.5V*Is t irn ,Ave I T] . Since implants are typically limited by the amount of available power, the design is optimized for high efficiency for higher capacity stimulation.
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In order to discriminate between shorting and stimulation states at an external reader, the modulation switch ensures a significant change in impedance. Backscatter amplitude is modulated by the electrical impedance load on the piezo (chip R[ N; changes with chip load) . The impedance of the modulation switch is designed to approximate the series resonant resistance of the piezo , where the backscatter profile is most sensitive to small change (Fig. 6 ). This allows for reader to distinguish between states even at a high load. The expected backscatter profile was simulated with a finite element method. stimulation parameters as a function of the input ultrasound . Backscattered ultrasound is measured at the end of shorting and stimulation phases (when free of acoustical feedthrough) using a second external hydrophone, providing a wireless single-bit indicator of the chips current state.
IV. IN VIVO M EAS UREMENTS
To validate the mote in vivo, the device was cuffed to the sciatic nerve of an anesthetized rodent (Fig. 8) at a depth of 2 I .5mm. All in vivo experiments were performed in compliance with the NIH Guide for the Care and Use of Laboratory Animals. Needle electrodes were inserted in the contracting muscle and motor unit potentials were recorded differentially. Test leads were used to monitor the electrode voltage as a function of time to demonstrate the delivery of stimulation current. Stimulation amplitude was swept to create intramuscular EMG recruitment curves that are consistent with established physiological measurements and demonstrates that the mote can deliver the full range of nerve activation intensities.
V. CON CLUSION
We compare agains t recently published implantable smallvolume and high-efficiency optical and electrical neurostimulators [3] - [6] in Table 1 . To our knowledge, this work achieves highest efficiency (82%) at the smalle st volume (6.5mm 3 ) and mass (I Omg), with the fewest external components, improving the FOM , defined as volume over efficiency, by 3.5x over stateof-the-art while delivering well-controlled stimulation capable of full-scale activation of a rodent sciatic nerve in vivo.
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